The newly appointed Supervisory Board of Merck KGaA re-elected Wolfgang Büchele as its Chairman at its constitutive meeting directly following the 24th Annual General Meeting. Michael Fletterich was also confirmed as Vice Chairman, representing the employee side. Apart from Büchele and Fletterich, four further shareholder representatives were elected by shareholders at the Annual General Meeting in Frankfurt am Main. Moreover, two shareholder representatives were directly appointed by E. Merck KG. The eight employee representative members had already been elected on April 11. The Supervisory Board members are appointed for the period until the end of the Annual General Meeting 2024, which is to resolve on the approval of actions for fiscal 2023.
The new Supervisory Board of Merck KGaA consists of the following members: Dr. Wolfgang Büchele (Chairman), Michael Fletterich (Vice Chairman), Dr. Gabriele Eismann, Edeltraud Glänzer, Jürgen Glaser, Sascha Held, Michael Kleinemeier, Renate Koehler, Anne Lange, Peter Emanuel Merck, Dr. Dietmar Oeter, Dr. Christian Raabe, Helene von Roeder, Prof. Dr. Helga Rübsamen-Schaeff, Dr. Daniel Thelen, and Dr. Simon Thelen.
The term of office of the previous Supervisory Board members expired upon conclusion of the 2019 Annual General Meeting. In addition, the Annual General Meeting approved the actions of the Executive Board and the Supervisory Board of Merck KGaA for fiscal 2018 by a large majority and approved all of the resolutions on the agenda, including the proposed dividend of € 1.25 per share. Merck is thus maintaining the dividend at a stable level although earnings per share pre (EPS pre), which is decisive for the dividend to be paid, declined in 2018.
Around 1,000 shareholders took part in the Annual General Meeting. When the resolutions were voted on, around 86.5 million shares were represented, corresponding to 66.96 % of the approximately 129.2 million shares issued.
